Lymphoma & Plasma Cell Disorders
News
FDA approves rituximab biosimilar for cancer, autoimmune disorders
The biosimilar is approved for certain cancers and autoimmune disorders, although, like its reference drug, it comes with a boxed warning from the...
Conference Coverage
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
From the Journals
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
From the Journals
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
News
Daratumumab wins new indication for newly diagnosed myeloma patients
Daratumumab plus lenalidomide and dexamethasone (DRd) is now approved for newly diagnosed myeloma patients who are ineligible for autologous stem...
Conference Coverage
Cell count ratios appear to predict thromboembolism in lymphoma
AMSTERDAM – The findings mean clinicians can look to complete blood count for answers on thromboembolism risk.
From the Journals
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.